Firibastat - Quantum Genomics

Drug Profile

Firibastat - Quantum Genomics

Alternative Names: Amino butane sulfonate disulfure; QGC 001; QGC-011; RB 150

Latest Information Update: 02 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNRS; INSERM; University Paris Descartes
  • Developer Quantum Genomics
  • Class Amines; Aminopeptidases; Antihypertensives; Cardiovascular therapies; Disulfides; Metalloexopeptidases; Sulfonic acids
  • Mechanism of Action Glutamyl aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Hypertension

Most Recent Events

  • 30 Oct 2018 Quantum Genomics plans a phase I trial for Healthy volunteers in January 2019 , (NCT03714685)
  • 23 Oct 2018 Quantum Genomics plans the phase IIb QUORUM trial for Left ventricular dysfunction in January 2019 (PO) (NCT03715998)
  • 18 Oct 2018 Quantum Genomics plans a clinical trial in healthy volunteers (Controlled-release) in the UK in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top